BOSTON, March 15, 2022 /PRNewswire/ -- NeuroBo
Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage
biotechnology company, today announced the appointment, effective
immediately, of Danamarie Belpulsi,
M.D., to its Scientific Advisory Board.
"Dr. Belpulsi brings to NeuroBo extensive expertise within a
number of highly relevant areas including infectious diseases,
cardiology and neurology, to name a few," stated Gil Price, M.D., President and Chief Executive
Officer of NeuroBo. "Additionally, her deep experience in the area
of clinical trial research and her strong relationships with key
opinion leaders, will be important as we move programs through the
clinic, going forward."
"I am delighted to join NeuroBo's Scientific Advisory Board,"
stated Dr. Belpulsi. "As the company continues to progress its lead
compound, ANA-001 and others, I intend to leverage my knowledge and
insights regarding clinical trial research, to make a meaningful
impact on the company's strategy and future success."
Dr. Belpulsi is currently Medical Director at ICON plc, a global
provider of consulting and outsourced development and
commercialization services to pharmaceutical, biotechnology,
medical device and government and public health
organizations. Before joining ICON plc., Dr. Belpulsi was the
Director of Drug Safety Solution, a company specializing in
Pharmacovigilance and Medical Monitoring of human clinical trials.
Earlier, Dr. Belpulsi contributed to clinical research trials
in the Department of Pathology & Cell Biology at Columbia University Medical Center College of
Physicians and Surgeons. Additionally, she is published in multiple
Throughout the years, Dr. Belpulsi has also acted as a
scientific consultant to companies such as Verseau Therapeutics,
Enkefalos Research, LLC and Juniper Pharmaceuticals (acquired by
Catalent, Inc.), lending her expertise and support to those
companies in the areas of immunology/oncology, neurology, pain
management and vaccines, among others.
Dr. Belpulsi earned a Doctor of Medicine, Medical Sciences
degree from the International American
University College of Medicine and attended the King's
College London, GKT School of Medical Education. She received a
Post Baccalaureate in Pre-Clinical Medicine from New York University's College of Arts and Science
and a Bachelor of Science degree from King's College, The College
of Arts and Sciences.
Forward Looking Statements
Any statements in this
press release that are not statements of historical fact constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements include, but are not limited to, statements regarding
NeuroBo's development expenses, the development of NeuroBo's
product candidates and the therapeutic potential, timing and nature
of clinical trials and potential regulatory approval of NeuroBo's
clinical programs and pipeline. Forward-looking statements are
usually identified by the use of words, such as "believes,"
"anticipates," "expects," "intends," "plans," "may," "potential,"
"will," "could" and similar expressions. Actual results may differ
materially from those indicated by forward-looking statements as a
result of various important factors and risks. These factors, risks
and uncertainties include, but are not limited to: recent changes
in NeuroBo's management; the failure to obtain all of the benefits
or recognize all of the synergies anticipated from the ANA
acquisition; the integration of ANA potentially diverting
management resources from operational matters and other strategic
opportunities; the effect of future milestone payments and
royalties specified in the ANA acquisition agreement on the results
of operations and financial position of NeuroBo; the occurrence of
health epidemics or contagious diseases, such as COVID-19, and
potential effects on NeuroBo's business, clinical trial sites,
supply chain and manufacturing facilities; NeuroBo's ability to
continue as a going concern; the timing of completion of NeuroBo's
planned clinical trials, including with respect to ANA001 and
Gemcabene; the timing of the availability of data from NeuroBo's
clinical trials, including with respect to ANA001 and Gemcabene;
NeuroBo's plans to research, develop and commercialize its current
and future product candidates, including the potential alternative
pathways for NB-01; NeuroBo's ability to successfully collaborate
with existing collaborators or enter into new collaborations and to
fulfill its obligations under any such collaboration agreements;
the clinical utility, potential benefits and market acceptance of
NeuroBo's product candidates, including ANA001 and Gemcabene; the
impact of government laws and regulations; NeuroBo's ability to
protect its intellectual property position; and NeuroBo's need for
additional financing to fulfill its stated goals. Please
refer to NeuroBo's most recent annual report on Form 10-K, as well
as NeuroBo's subsequent filings on Form 10-Q and Form 8-K, which
are available on the SEC's website (www.sec.gov), for a full
discussion of the risks and other factors that may impact any
forward-looking statements in this press release. In addition, the
forward-looking statements included in this press release represent
NeuroBo's views as of the date hereof. NeuroBo anticipates that
subsequent events and developments will cause its views to change.
However, while NeuroBo may elect to update these forward-looking
statements at some point in the future, NeuroBo specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing NeuroBo's views as of any
date subsequent to the date hereof.
Rx Communications Group
SOURCE NeuroBo Pharmaceuticals, Inc.